Spark completes rolling BLA submission for voretigene neparvovec

Spark Therapeutics Inc. (NASDAQ:ONCE) completed submission of a rolling BLA to FDA for voretigene neparvovec (AAV2-hRPE65v2) to treat patients with vision loss due to confirmed, biallelic, retinal pi...